Pharmamarketeer

Bristol─Myers Squibb gets European nod for Empliciti plus pomalidomide & low─dose dexamethasone to treat MM

Bristol─Myers Squibb Company announced that the European Commission (EC) has approved Empliciti (elotuzumab) plus pomalidomide and low─dose dexamethasone (EPd) for the treatment of adult patients

Medhc-fases-banner
Advertentie(s)